Pure Global
NCT05055193

Outcome of Extremely Preterm Infants Who Received Systemic Postnatal Corticosteroid for Bronchopulmonary Dysplasia

Hospices Civils de Lyon·ClinicalTrials.gov·drugCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Bronchopulmonary Dysplasia
Drug/Device/Intervention
Evaluation at 24 months corrected age: respiratory outcome, Neurodevelopmental outcome, Growth outcome
Study type
Observational
Intervention type
drug
Sponsor & location
Primary sponsor
Hospices Civils de Lyon
Location
Lyon, France
Timeline & enrollment
Phase
N/A
Start date
Jan 01, 2013
End date
Dec 31, 2018
Enrollment
400 participants
Primary outcome

Composite primary outcome combining: - Respiratory evolution at 24 months corrected age - Neurodevelopmental evolution at 24 months corrected age - Growth evolution at 24 months corrected age

Summary

Bronchopulmonary dysplasia is a complication of prematurity. Postnatal corticosteroid is used
 to treat the inflammatory part of this pathology, in particular to wean premature infants
 from the ventilator at the end of the first month of life. However, this therapy remains
 controversial because it may induce suboptimal neurocognitive development. Parents of infants
 who receive postnatal corticosteroid should be provided with information about the risks. The
 objective of our work was to evaluate the respiratory, neurodevelopmental and growth outcomes
 at 24 months corrected age of extremely preterm infants who received postnatal
 corticosteroid.

ICD-10 classifications
Bronchopulmonary dysplasia originating in the perinatal periodCongenital bronchomalaciaBronchopneumonia, unspecifiedOther congenital malformations of bronchusDiseases of bronchus, not elsewhere classified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05055193
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05055193 through Pure Global AI's free database. This phase not specified trial is sponsored by Hospices Civils de Lyon and is currently Completed. The study focuses on Bronchopulmonary Dysplasia. Target enrollment is 400 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.